HistoSonics reaches $2.25B valuation after investor-led majority acquisition - The Robot Report

HistoSonics, a medical technology company specializing in non-invasive tumor treatment using histotripsy, has reached a valuation of approximately $2.25 billion following a management-led majority acquisition by a syndicate of private and public investors, including K5 Global, Bezos Expeditions, and Wellington Management. The company’s flagship product, the Edison System, delivers pulsed sound energy to mechanically destroy tumors without incisions or needles. With FDA de novo clearance granted in October 2023, Edison has treated over 2,000 patients across more than 50 U.S. medical centers, with plans for further installations and expanded market access, including limited approval in the U.K. The new investment will enable HistoSonics to accelerate growth and broaden the clinical applications of its technology beyond liver tumors to include kidney, pancreas, and prostate indications. The company is actively enrolling patients in clinical trials for these conditions and aims to extend histotripsy’s use to treat a wide range of benign and malignant